A-29.01, r. 2.1 - Regulation respecting exceptions to the prohibition against paying or reimbursing the price of a medication or supply covered by the basic prescription drug insurance plan

Occurrences0
Full text
Updated to 1 July 2022
This document has official status.
chapter A-29.01, r. 2.1
Regulation respecting exceptions to the prohibition against paying or reimbursing the price of a medication or supply covered by the basic prescription drug insurance plan
Act respecting prescription drug insurance
(chapter A-29.01, s. 80.2, par. 1).
1. An accredited manufacturer or wholesaler or an intermediary may pay or reimburse to a person covered by the basic prescription drug insurance plan all or part of the price of the following medications:
(1)  those entered on the list drawn up by the Minister under section 60 of the Act respecting prescription drug insurance (chapter A-29.01) for which the lowest price method does not apply;
(2)  those for which a generic or biosimilar version is not entered on the list drawn up by the Minister under section 60 of the Act.
M.O. 2021-014, s. 1.
2. Where a medication that was referred to in section 1 ceases to be referred to in that section, an accredited manufacturer or wholesaler or an intermediary may continue to pay or reimburse to a person covered by the basic prescription drug insurance plan all or part of the price of the medication for a maximum period of 30 days following the beginning of the application of the lowest price method to the medication or the entry of a generic or biosimilar version on the list drawn up by the Minister under section 60 of the Act, as the case may be.
M.O. 2021-014, s. 2.
3. An accredited manufacturer or wholesaler or an intermediary may continue to pay or reimburse to a person covered by the basic prescription drug insurance plan all or part of the price of a medication that is not referred to in section 1 if, before the coming into force of paragraph 1 of section 80.2 of the Act, that person has already received such a payment or reimbursement for that medication.
M.O. 2021-014, s. 3.
4. (Omitted).
M.O. 2021-014, s. 4.
REFERENCES
M.O. 2021-014, 2021 G.O. 2, 1183